UA105405C2 - Гуманизированное антитело против человеческого il-22ra - Google Patents

Гуманизированное антитело против человеческого il-22ra

Info

Publication number
UA105405C2
UA105405C2 UAA201207335A UAA201207335A UA105405C2 UA 105405 C2 UA105405 C2 UA 105405C2 UA A201207335 A UAA201207335 A UA A201207335A UA A201207335 A UAA201207335 A UA A201207335A UA 105405 C2 UA105405 C2 UA 105405C2
Authority
UA
Ukraine
Prior art keywords
antibody
humanized anti
psoriasis
imunooposeredkovanikh
atopichniy
Prior art date
Application number
UAA201207335A
Other languages
English (en)
Ukrainian (uk)
Inventor
Роланд Бекманн
Керолайн Джонсон-Леджер
Original Assignee
Мерк Сероно С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41565648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA105405(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Сероно С.А. filed Critical Мерк Сероно С.А.
Publication of UA105405C2 publication Critical patent/UA105405C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относится к к гуманизированному антителу против человеческого Il-22ra и его применения в лечении псориаза и других имуноопосередкованных заболеваний, таких как псориатический артрит и атопический дерматит.
UAA201207335A 2009-11-19 2010-11-12 Гуманизированное антитело против человеческого il-22ra UA105405C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09176525 2009-11-19
PCT/EP2010/067332 WO2011061119A1 (en) 2009-11-19 2010-11-12 Humanized antibodies against human il-22ra

Publications (1)

Publication Number Publication Date
UA105405C2 true UA105405C2 (ru) 2014-05-12

Family

ID=41565648

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201207335A UA105405C2 (ru) 2009-11-19 2010-11-12 Гуманизированное антитело против человеческого il-22ra

Country Status (19)

Country Link
US (1) US8545844B2 (ru)
EP (1) EP2512511B1 (ru)
JP (1) JP5818804B2 (ru)
KR (1) KR20120098783A (ru)
CN (1) CN102665759B (ru)
AU (1) AU2010321047B2 (ru)
BR (1) BR112012012003A2 (ru)
CA (1) CA2778864C (ru)
EA (1) EA021356B1 (ru)
EC (1) ECSP12011980A (ru)
ES (1) ES2531996T3 (ru)
IL (1) IL219740A0 (ru)
IN (1) IN2012DN03362A (ru)
MX (1) MX2012005791A (ru)
NZ (1) NZ599438A (ru)
PE (1) PE20121560A1 (ru)
UA (1) UA105405C2 (ru)
WO (1) WO2011061119A1 (ru)
ZA (1) ZA201202793B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0516975A (pt) * 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
ES2670874T3 (es) 2011-03-16 2018-06-01 Argenx Bvba Anticuerpos contra CD70
KR20160042438A (ko) 2013-08-12 2016-04-19 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
US10179821B2 (en) * 2014-05-01 2019-01-15 Genentech, Inc. Anti-factor D antibodies
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
US10654932B2 (en) * 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
EP4292649A3 (en) 2016-03-18 2024-02-21 Staidson(Beijing) Biopharmaceuticals Co., Ltd. Fusion protein comprising nerve growth factor and preparation method and use thereof
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
US10781265B2 (en) * 2017-05-24 2020-09-22 Development Center For Biotechnology Humanized antibodies against Globo H and uses thereof in cancer treatments
RU2019142330A (ru) 2017-06-30 2021-07-30 Займворкс, Инк. Стабилизированные химерные fab
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2023232789A1 (en) * 2022-06-03 2023-12-07 Leo Pharma A/S Liquid formulation of il-22r antibody
WO2024184333A1 (en) 2023-03-08 2024-09-12 Leo Pharma A/S Il-22r antibody for use in treating atopic dermatitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
BRPI0516975A (pt) * 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
TW200720439A (en) * 2005-03-25 2007-06-01 Glycart Biotechnology Ag Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
NZ621483A (en) * 2005-12-02 2015-10-30 Genentech Inc Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r

Also Published As

Publication number Publication date
JP2013511267A (ja) 2013-04-04
PE20121560A1 (es) 2012-12-05
MX2012005791A (es) 2012-07-03
IL219740A0 (en) 2012-07-31
CA2778864C (en) 2017-06-27
EP2512511A1 (en) 2012-10-24
AU2010321047B2 (en) 2016-06-09
IN2012DN03362A (ru) 2015-10-23
US8545844B2 (en) 2013-10-01
CA2778864A1 (en) 2011-05-26
AU2010321047A1 (en) 2012-05-24
US20120230990A1 (en) 2012-09-13
NZ599438A (en) 2013-12-20
JP5818804B2 (ja) 2015-11-18
EA201290360A1 (ru) 2012-11-30
BR112012012003A2 (pt) 2016-11-29
EP2512511B1 (en) 2015-01-07
ZA201202793B (en) 2013-06-26
ECSP12011980A (es) 2012-07-31
EA021356B1 (ru) 2015-05-29
CN102665759B (zh) 2015-09-30
CN102665759A (zh) 2012-09-12
KR20120098783A (ko) 2012-09-05
ES2531996T3 (es) 2015-03-23
WO2011061119A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
UA105405C2 (ru) Гуманизированное антитело против человеческого il-22ra
IN2012DN01920A (ru)
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
UA109658C2 (xx) Антитіло проти cgrp
AU2011338383A8 (en) Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
IN2012DN02081A (ru)
PH12014501595A1 (en) Substituted annulated pyrimidines and triazines, and use thereof
MX2009009079A (es) Anticuerpos anti-il-23p19 de ingenieria.
MX2009009080A (es) Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
WO2011143318A3 (en) Anti-fgfr2 antibodies
IN2012DN00624A (ru)
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
MX2009011500A (es) Anticuerpos anti-mdl-1.
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
UA106890C2 (ru) Гуманизированное антитело к cdcp1
GB201109238D0 (en) Antibodies
MX354988B (es) Formulaciones de anticuerpo y metodos.
UA103916C2 (en) Dkk-1 antibody
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.